The demand for spinal pain treatment options in the United States is expected to rise at a CAGR of 10.6% during the forecast period. Total revenue in the country is projected to increase from US$ 3,962.7 million in 2023 to US$ 10,962.7 million by 2033. In 2022, overall sales totaled around US$ 3,635.2 million in the United States.
Key Highlights
Revenue in the United States is projected to expand around 2.8X through 2033, amid a 3.2% increase in expected CAGR compared to the historical one. This is attributable to the growing prevalence of back pain and rising patient spending on spine pain management.
As per the latest United States spine pain industry analysis and trends, the spinal non-fusion segment is expected to hold a dominant value share of around 36.8% in 2033. This is attributable to the rising popularity of spinal non-fusion surgery. This type of surgery is gaining momentum due to its benefits, including less pain, fast recovery time, reduced risk of complications, and preservation of spinal motion.
| Attributes | Key Insights |
|---|---|
| United States Spine Pain Business Revenue in 2022 | US$ 3,635.2 million |
| Estimated Value in 2023 | US$ 3,962.7 million |
| Projected Value in 2033 | US$ 10,962.7 million |
| Value-based CAGR (2023 to 2033) | 10.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The spine pain business encompasses the analysis of multiple spinal pains and their respective therapeutic approaches aimed at addressing unmet needs and improving the quality of life for individuals. It is expected to flourish during the forecast period due to several factors, including the rising prevalence of back pain.
The growing prevalence of back pain in the United States is a prominent factor expected to drive demand during the forecast period. This is because patients suffering from back pain often opt for different treatments.
In recent years, there has been a spike in cases of back pain across the United States due to factors such as sedentary lifestyles, weight gain, and poor posture. As per the National Center for Health Statistics, around 39.0% of adults suffered from back pain in 2019. This dramatic rise in back pain is expected to boost sales growth in the United States.
Principal Consultant
Spine pain product sales in the United States increased at a CAGR of 7.4% between 2018 and 2022. Over the assessment period, the United States is poised to exhibit a CAGR of 10.6%.
| Historical CAGR (2018 to 2022) | 7.4% |
|---|---|
| Forecast CAGR (2023 to 2033) | 10.6% |
The demand for patient-centric care is of utmost importance and a transformative trend in the spine pain business. It is mainly driven by a shift in patient expectations and recognition of the importance of tailoring care to individual needs. This trend reflects the growing desire of patients to play an active role in their healthcare decisions and to receive treatments that align with their unique circumstances, preferences, and lifestyles.
Patients are increasingly looking for treatments that recognize their unique pain experiences, taking into account elements, including pain intensity, impact on everyday life, and individual pain thresholds. This demand encourages healthcare providers to have meaningful dialogues with patients, listen carefully to their concerns, and collaborate to build treatment programs that represent their individual pain profiles.
The increasing need for patient-centered care in the spine pain business represents a fundamental shift in the healthcare landscape. This is expected to boost revenue in the United States through 2033.
Mobile apps designed for spine pain management can serve as versatile tools that empower patients to participate actively in their treatment journey. These apps can provide personalized exercise regimens, pain-tracking functionalities, and educational resources, allowing patients to better understand their condition and adhere to recommended therapies.
By engaging patients in their care, these apps foster a sense of ownership and accountability. They potentially lead to more effective pain management and a reduced reliance on acute interventions.
Multidisciplinary back pain apps such as the Kaia app for use on mobile devices have shown greater effectiveness than physiotherapy in combination with online education in treating patients with lower back pain. These results support those of another large study of more than 10,000 adults that showed a digital care program available through a mobile app resulted in a significant positive relationship between engagement and pain reduction.
Interdisciplinary collaboration represents a transformative opportunity in the spine pain business and a shift toward comprehensive & patient-centered care. In a landscape where spine pain often extends beyond physical discomfort to encompass psychological and emotional burdens, collaborative care models bring together experts from diverse fields.
Collaborative care models can also bring together surgeons, pain management specialists, physiotherapists, and psychologists to offer holistic treatment approaches that address the multifaceted nature of spine pain. This is set to bode well for the target business in the United States.
The interdisciplinary collaboration lies in the recognition that spine pain isn't solely a mechanical issue. It encompasses physiological, psychological, and even social dimensions.
Orthopedic spine surgeons in the United States contribute their expertise in diagnosing structural issues and performing necessary surgical interventions. Pain management specialists would play a crucial role in providing effective pain relief strategies, ensuring that patients experience comfort while undergoing treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Patients who lack comprehensive health insurance coverage or have high deductibles can find themselves unable to afford the necessary interventions for their spine pain. This finanacial strain can compel patients to delay or altogether forgo treatments, leading to exacerbated pain, reduced quality of life, and an increased potential for long-term complications. Consequently, the pool of potential patients who can benefit from these treatments shrinks, adversely affecting the industry’s expansion.
The economic burden extends beyond individuals to healthcare systems and insurers. The high costs of spine pain treatments strain healthcare budgets and contribute to rising healthcare expenditures. This financial stress can result in tougher decisions on reimbursement policies and coverage limitations, further restricting patients' options for receiving timely and appropriate care.
Growth Outlook by Key State
| States | Value-based CAGR |
|---|---|
| South Carolina | 9.9% |
| Florida | 11.3% |
| Virginia | 10.7% |
| North Carolina | 10.4% |
| California | 11.7% |
Sales in South Carolina are expected to rise at 9.9% CAGR during the forecast period. This is attributable to the rising prevalence of spine-related issues and the presence of well-established healthcare infrastructure.
The high prevalence of obesity in South Carolina is closely related to the increasing incidence of spine-related issues. As there are several healthcare facilities in South Carolina, such as hospitals, clinics, and specialist centers, these institutions offer spine pain management services. These are estimated to improve access to care and contribute to sales growth.
The state boasts orthopedic and neurosurgical experts who specialize in spine pain treatment and surgery. This expertise is expected to attract patients seeking advanced care, particularly for complex spine conditions.
Demand in Florida is projected to increase at a CAGR of 11.3% during the assessment period. This can be attributed to the presence of several specialized spine pain treatment centers in the state and growing cases of spine diseases.
Florida hosts several specialized spine pain treatment centers, drawing patients from all over the United States. These centers offer a wide range of services, including surgical and non-surgical interventions.
Florida's focus on pain management services has led to the establishment of specialized pain clinics offering interventional and medication-based pain relief solutions. The growing inclination of patients to opt for treatments in these clinics will likely boost revenue in Florida.
The below section highlights the prediction for the spinal non fusion segment, which is expected to hold a dominant share based on product type. It is expected to exhibit a CAGR of 10.5% through 2033.
Based on pain type, the thoracolumbar pain segment is anticipated to lead the United States. It will likely progress at 8.9% CAGR during the assessment period.
In terms of end users, the hospital segment is set to generate significant revenue in the United States. It is poised to thrive at a CAGR of 7.1% between 2023 and 2023.
Growth Outlook by Key Product Type
| Product | Value-based CAGR |
|---|---|
| Spinal Fusion | 7.5% |
| Spinal Non Fusion | 10.5% |
| Vertebral Body Replacement Systems | 10.6% |
| Spinal Cord Stimulation | 15.5% |
| Transcutaneous Electrical Neuromuscular Stimulation (TENS) | 13.0% |
| Spinal Epidural Injection | 13.1% |
As per the latest United States spine pain industry analysis, the spinal non-fusion segment is projected to thrive at a CAGR of 10.5% during the forecast period. By 2033, the target segment is set to reach US$ 4,033.3 million.
The rising usage of spinal non-fusion devices to treat spinal disorders without permanently connecting or fusing vertebrae together is expected to boost the segment. These medical implants or devices are set to be used to treat disorders, such as spinal instability, discomfort, and disc problems while permitting natural movement of the spine.
A handful of examples of spine non-fusion devices include facet arthroplasty devices, annulus repair devices, artificial disc replacement systems, nuclear disc prostheses, interspinous process decompression (IPD) devices, and pedicle screw-based dynamic stabilization systems.
Growth Outlook by Pain Type
| Pain Type | Value-based CAGR |
|---|---|
| Cervical Pain | 12.2% |
| Thoracolumbar Pain | 8.9% |
| Lumbar Pain | 11.0% |
| Sciatic Pain | 10.7% |
Based on pain type, the thoracolumbar pain segment is expected to progress at a CAGR of 8.9% during the assessment period. It will likely total a valuation of US$ 1,554.8 million in 2023.
Patients in the United States often grapple with thoracolumbar pain, which resides in the mid-back where the thoracic and lumbar spine meet. This discomfort arises from irritation of the thoracolumbar facet joints. When it comes to managing or resolving this pain, they have a range of treatment options to consider.
Management of thoracolumbar pain frequently involves physical therapy and rehabilitation. The demand for these services has led to an expansion of physical therapy clinics and rehabilitation facilities, which contributes to the sales growth in the United States.
The treatment often includes pain medications, nerve blocks, and other interventional therapies. These pharmaceutical and medical interventions are expected to drive growth in the pharmaceutical and medical device sectors, thereby boosting revenue in the United States.
Growth Outlook by Key End User
| Application | Value-based CAGR |
|---|---|
| Hospitals | 7.1% |
| Specialty Clinic | 11.5% |
| Ambulatory Surgical Centers | 14.6% |
The hospital segment is anticipated to expand at 7.1% CAGR over the forecast period. It is predicted to total a valuation of US$ 1,925.2 million by 2033.
Hospitals are typically located in convenient and accessible locations, making it easier for patients to seek care for spine pain without the need for a hospital visit. This accessibility encourages more people to access treatment, ultimately expanding the patient base in hospitals.
The ambulatory care center segment is expected to witness a higher CAGR of 14.6% through 2033. Ambulatory care centers often offer shorter wait times compared to traditional hospitals. Patients with spine pain can receive timely evaluations, diagnostic tests, and treatment, leading to faster relief and improved patient satisfaction.
Key players are focusing on introducing novel solutions for back pain. Strategic partnerships are a priority for leading United States-based spine pain solution providers. Several players are also investing in research and development as well as implementing strategies, including acquisitions, mergers, and collaborations, to solidify their positions.
Recent Developments in Spine Pain Therapy Business
| Attribute | Details |
|---|---|
| Estimated Size (2023) | US$ 3,962.7 million |
| Projected Value (2033) | US$ 10,962.7 million |
| Anticipated Growth Rate (2023 to 2033) | 10.6% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Industry Analysis | Value (US$ million) |
| Key Regions Covered | Northeast; Midwest; Southeast; Southwest; West |
| Key States Covered | New York, New Jersey, Massachusetts, Rest of North East, Minnesota, Wisconsin, Rest of Midwest, North Carolina, South Carolina, Florida, Virginia, Rest of Southeast, Louisiana, Oklahoma, Texas, Rest of Southeast, Washington, California, New Mexico, Rest of West |
| Key Segments Covered | Product Type, Pain Type, End User, and Region |
| Key Companies Profiled | Zimmer, Inc. (ZimVie Inc.); Medtronic; Johnson & Johnson; Stryker Corporation; Abbott Laboratories; Boston Scientific Corporation; B Braun (Aesculap, Inc.); Becton, Dickinson and Company; Globus Medical; Alphatec Spine, Inc.; Nevro Corp; NuVasive, Inc.; Orthofix US LLC.; Surgalign Spine Technologies, Inc.; Precision Spine, Inc. |
| Report Coverage | Sales Forecast, Competition Intelligence, Key Dynamics and Challenges, Strategic Growth Initiatives |
Revenue in the United States is set to reach US$ 3,962.7 million by 2023.
Sales in the United States are expected to total US$ 10,962.7 million by 2033.
Demand in the United States is set to rise at 10.6% CAGR through 2033.
The spinal non-fusion segment held around 37.2% share in 2022.
Sales in the United States increased at 7.4% CAGR from 2018 to 2022.
The Southeast region accounted for 36.6% value share in 2022.
About 29.9% of people aged 18 and older suffered from lower back pain in 2018.
Around US$ 50 billion is spent by people in the United States on back pain each year.
1. Executive Summary 1.1. United States Industry Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Overview 2.1. Coverage / Taxonomy 2.2. Product Definition / Scope / Limitations 2.3. Inclusions & Exclusions 3. Key Trends 3.1. Key Trends Impacting Sales 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Product Assessment 4.1.1. Product Adoption Analysis 4.1.2. Product USP's/Features Analysis 4.1.3. Recent Product Launches and Innovations 4.1.4. Product Matrix Analysis 4.2. Number of Procedures 4.3. Regulatory Landscape 4.4. Reimbursement Scenario 4.4.1. Reimbursement Guidelines 4.4.2. Reimbursement Codes 4.4.3. Payer Mix Analysis 4.5. PESTLE Analysis 4.6. Porter’s Analysis 5. Background 5.1. Macro-Economic Factors 5.1.1. United States Healthcare Expenditure 5.1.2. United States R&D Funding 5.1.3. United States Medical Device Industry Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Obesity Epidemic 5.2.2. Technological Advancements 5.2.3. Regulatory Changes 5.2.4. Telemedicine Adoption 5.2.5. Pain Management Solutions 5.2.6. Posture and Lifestyle Changes 5.2.7. Economic Factors 5.2.8. Competition and Key Players 5.2.9. Healthcare Infrastructure 5.3. Key Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Volume (Units) Analysis 2018 to 2022 and Forecast, 2023 to 2033 6.1. Historical Volume (Units) Analysis, 2018 to 2022 6.2. Current and Future Volume (Units) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 7. Demand Pricing Analysis 7.1. Average Pricing Analysis Benchmark 7.2. Pricing Break-up 7.2.1. Manufacturer Level Pricing 7.2.2. Distributor Level Pricing 7.3. Pricing Assumptions 8. Demand (in Value or Size in US$ million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 8.1. Revenue Opportunity Scenario 8.2. Historical Value (US$ million) Analysis, 2018 to 2022 8.3. Current and Future Value (US$ million) Projections, 2023 to 2033 8.3.1. Y-o-Y Growth Trend Analysis 8.3.2. Absolute $ Opportunity Analysis 9. Demand Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 9.1. Introduction / Key Findings 9.2. Historical Size (US$ million) and Volume (Units) Analysis by Product Type, 2018 to 2022 9.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast by Product Type, 2023 to 2033 9.3.1. Spinal Fusion 9.3.1.1. Interbody Devices 9.3.1.2. Pedicle Screw Systems 9.3.1.3. Spinal Plating Systems 9.3.2. Spinal Non-fusion 9.3.2.1. Annulus Repair Devices 9.3.2.2. Artificial Disc Replacement Systems 9.3.2.3. Interspinous Process Decompression (IPD) Devices 9.3.2.4. Pedicle Screw-based Dynamic Stabilization Systems 9.3.3. Vertebral Body Replacement Systems 9.3.4. Spinal Cord Stimulation 9.3.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS) 9.3.6. Spinal Epidural Injection 9.4. Attractiveness Analysis by Product Type 10. Demand Analysis 2018 to 2022 and Forecast 2023 to 2033, By Pain Type 10.1. Introduction / Key Findings 10.2. Historical Size (US$ million) Analysis by Pain Type, 2018 to 2022 10.3. Current and Future Size (US$ million) Analysis and Forecast by Pain Type, 2023 to 2033 10.3.1. Cervical Pain 10.3.1.1. Arm Pain 10.3.2. Thoracolumbar Pain 10.3.2.1. Arm Pain 10.3.2.2. Leg Pain 10.3.3. Lumbar Pain 10.3.3.1. Leg Pain 10.3.4. Sciatic Pain 10.3.4.1. Leg Pain 10.4. Attractiveness Analysis by Pain Type 11. Demand Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 11.1. Introduction / Key Findings 11.2. Historical Size (US$ million) Analysis by End User, 2018 to 2022 11.3. Current and Future Size (US$ million) Analysis and Forecast By End User, 2023 to 2033 11.3.1. Hospitals 11.3.2. Specialty Clinics 11.3.3. Ambulatory Surgical Centers 11.4. Attractiveness Analysis by End User 12. Demand Analysis: Cross-Sectional Analysis - Pain Type Vs Product Type 12.1. Historical Size (US$ million) Product Type Vs Pain Type, 2018 to 2022 12.2. Current and Future Size (US$ million) Analysis and Forecast Product Type Vs Pain Type 2023 to 2033 12.2.1. Cervical Pain 12.2.1.1. Spinal Fusion 12.2.1.1.1. Interbody Devices 12.2.1.1.2. Pedicle Screw Systems 12.2.1.1.3. Spinal Plating Systems 12.2.1.2. Spinal Non-Fusion 12.2.1.2.1. Annulus Repair Devices 12.2.1.2.2. Artificial Disc Replacement Systems 12.2.1.2.3. Interspinous Process Decompression (IPD) Devices 12.2.1.2.4. Pedicle Screw-Based Dynamic Stabilization Systems 12.2.1.3. Vertebral Body Replacement Systems 12.2.1.4. Spinal Cord Stimulation 12.2.1.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS) 12.2.1.6. Spinal Epidural Injection 12.2.2. Thoracolumbar Pain 12.2.2.1. Spinal Fusion 12.2.2.1.1. Interbody Devices 12.2.2.1.2. Pedicle Screw Systems 12.2.2.1.3. Spinal Plating Systems 12.2.2.2. Spinal Non-Fusion 12.2.2.2.1. Annulus Repair Devices 12.2.2.2.2. Artificial Disc Replacement Systems 12.2.2.2.3. Interspinous Process Decompression (IPD) Devices 12.2.2.2.4. Pedicle Screw-Based Dynamic Stabilization Systems 12.2.2.3. Vertebral Body Replacement Systems 12.2.2.4. Spinal Cord Stimulation 12.2.2.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS) 12.2.2.6. Spinal Epidural Injection 12.2.3. Lumbar Pain 12.2.3.1. Spinal Fusion 12.2.3.1.1. Interbody Devices 12.2.3.1.2. Pedicle Screw Systems 12.2.3.1.3. Spinal Plating Systems 12.2.3.2. Spinal Non-Fusion 12.2.3.2.1. Annulus Repair Devices 12.2.3.2.2. Artificial Disc Replacement Systems 12.2.3.2.3. Interspinous Process Decompression (IPD) Devices 12.2.3.2.4. Pedicle Screw-Based Dynamic Stabilization Systems 12.2.3.3. Vertebral Body Replacement Systems 12.2.3.4. Spinal Cord Stimulation 12.2.3.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS) 12.2.3.6. Spinal Epidural Injection 12.2.4. Sciatic Pain 12.2.4.1. Spinal Fusion 12.2.4.1.1. Interbody Devices 12.2.4.1.2. Pedicle Screw Systems 12.2.4.1.3. Spinal Plating Systems 12.2.4.2. Spinal Non-Fusion 12.2.4.2.1. Annulus Repair Devices 12.2.4.2.2. Artificial Disc Replacement Systems 12.2.4.2.3. Interspinous Process Decompression (IPD) Devices 12.2.4.2.4. Pedicle Screw-Based Dynamic Stabilization Systems 12.2.4.3. Vertebral Body Replacement Systems 12.2.4.4. Spinal Cord Stimulation 12.2.4.5. Transcutaneous Electrical Neuromuscular Stimulation (TENS) 12.2.4.6. Spinal Epidural Injection 13. United States Demand Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region 13.1. Introduction 13.2. Historical Size (US$ million) and Volume (Units) Analysis, By Region, 2018 to 2022 13.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033 13.3.1. Northeast 13.3.2. Midwest 13.3.3. Southeast 13.3.4. Southwest 13.3.5. West 13.4. Attractiveness Analysis by Region 14. Northeast Demand Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022 14.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033 14.3.1. By States 14.3.1.1. New York 14.3.1.2. New Jersey 14.3.1.3. Massachusetts 14.3.1.4. Rest of North East 14.3.2. By Product Type 14.3.3. By Pain Type 14.3.4. By End User 14.4. Attractiveness Analysis 14.4.1. By States 14.4.2. By Product Type 14.4.3. By Pain Type 14.4.4. By End User 14.5. Key Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 14.7. State Level Analysis & Forecast 14.7.1. New York Demand Analysis 14.7.1.1. Introduction 14.7.1.2. Demand Analysis and Forecast by Taxonomy 14.7.1.2.1. By Product Type 14.7.1.2.2. By Pain Type 14.7.1.2.3. By End User 14.7.2. New Jersey Demand Analysis 14.7.2.1. Introduction 14.7.2.2. Demand Analysis and Forecast by Taxonomy 14.7.2.2.1. By Product Type 14.7.2.2.2. By Pain Type 14.7.2.2.3. By End User 14.7.3. Massachusetts Demand Analysis 14.7.3.1. Introduction 14.7.3.2. Demand Analysis and Forecast by Taxonomy 14.7.3.2.1. By Product Type 14.7.3.2.2. By Pain Type 14.7.3.2.3. By End User 15. Midwest Demand Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022 15.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033 15.3.1. By States 15.3.1.1. Minnesota 15.3.1.2. Wisconsin 15.3.1.3. Rest of Midwest 15.3.2. By Product Type 15.3.3. By Pain Type 15.3.4. By End User 15.4. Attractiveness Analysis 15.4.1. By States 15.4.2. By Product Type 15.4.3. By Pain Type 15.4.4. By End User 15.5. States Level Analysis & Forecast 15.5.1. Minnesota Demand Analysis 15.5.1.1. Introduction 15.5.1.2. Demand Analysis and Forecast by Taxonomy 15.5.1.2.1. By Product Type 15.5.1.2.2. By Pain Type 15.5.1.2.3. By End User 15.5.2. Wisconsin Demand Analysis 15.5.2.1. Introduction 15.5.2.2. Demand Analysis and Forecast by Taxonomy 15.5.2.2.1. By Product Type 15.5.2.2.2. By Pain Type 15.5.2.2.3. By End User 16. Southeast Demand Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022 16.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033 16.3.1. By States 16.3.1.1. North Carolina 16.3.1.2. South Carolina 16.3.1.3. Florida 16.3.1.4. Virginia 16.3.1.5. Rest of Southeast 16.3.2. By Product Type 16.3.3. By Pain Type 16.3.4. By End User 16.4. Attractiveness Analysis 16.4.1. By States 16.4.2. By Product Type 16.4.3. By Pain Type 16.4.4. By End User 16.5. Drivers and Restraints - Impact Analysis 16.6. State Level Analysis & Forecast 16.6.1. North Carolina Demand Analysis 16.6.1.1. Introduction 16.6.1.2. Demand Analysis and Forecast by Taxonomy 16.6.1.2.1. By Product Type 16.6.1.2.2. By Pain Type 16.6.1.2.3. By End User 16.6.2. South Carolina Demand Analysis 16.6.2.1. Introduction 16.6.2.2. Demand Analysis and Forecast by Taxonomy 16.6.2.2.1. By Product Type 16.6.2.2.2. By Pain Type 16.6.2.2.3. By End User 16.6.3. Florida Demand Analysis 16.6.3.1. Introduction 16.6.3.2. Demand Analysis and Forecast by Taxonomy 16.6.3.2.1. By Product Type 16.6.3.2.2. By Pain Type 16.6.3.2.3. By End User 16.6.4. Virginia Demand Analysis 16.6.4.1. Introduction 16.6.4.2. Demand Analysis and Forecast by Taxonomy 16.6.4.2.1. By Product Type 16.6.4.2.2. By Pain Type 16.6.4.2.3. By End User 17. Southwest Demand Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022 17.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033 17.3.1. By States 17.3.1.1. Louisiana 17.3.1.2. Oklahoma 17.3.1.3. Texas 17.3.1.4. Rest of Southwest 17.3.2. By Product Type 17.3.3. By Pain Type 17.3.4. By End User 17.4. Attractiveness Analysis 17.4.1. By States 17.4.2. By Product Type 17.4.3. By Pain Type 17.4.4. By End User 17.5. Drivers and Restraints - Impact Analysis 17.6. State Level Analysis & Forecast 17.6.1. Louisiana Demand Analysis 17.6.1.1. Introduction 17.6.1.2. Demand Analysis and Forecast by Taxonomy 17.6.1.2.1. By Product Type 17.6.1.2.2. By Pain Type 17.6.1.2.3. By End User 17.6.2. Oklahoma Demand Analysis 17.6.2.1. Introduction 17.6.2.2. Demand Analysis and Forecast by Taxonomy 17.6.2.2.1. By Product Type 17.6.2.2.2. By Pain Type 17.6.2.2.3. By End User 17.6.3. Texas Demand Analysis 17.6.3.1. Introduction 17.6.3.2. Demand Analysis and Forecast by Taxonomy 17.6.3.2.1. By Product Type 17.6.3.2.2. By Pain Type 17.6.3.2.3. By End User 18. West Demand Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Size (US$ million) and Volume (Units) Trend Analysis by Taxonomy, 2018 to 2022 18.3. Current and Future Size (US$ million) and Volume (Units) Analysis and Forecast By Taxonomy, 2023 to 2033 18.3.1. By States 18.3.1.1. Washington 18.3.1.2. California 18.3.1.3. New Mexico 18.3.1.4. Rest of West 18.3.2. By Product Type 18.3.3. By Pain Type 18.3.4. By End User 18.4. Attractiveness Analysis 18.4.1. By States 18.4.2. By Product Type 18.4.3. By Pain Type 18.4.4. By End User 18.5. Drivers and Restraints - Impact Analysis 18.6. State Level Analysis & Forecast 18.6.1. Washington Demand Analysis 18.6.1.1. Introduction 18.6.1.2. Demand Analysis and Forecast by Taxonomy 18.6.1.2.1. By Product Type 18.6.1.2.2. By Pain Type 18.6.1.2.3. By End User 18.6.2. California Demand Analysis 18.6.2.1. Introduction 18.6.2.2. Demand Analysis and Forecast by Taxonomy 18.6.2.2.1. By Product Type 18.6.2.2.2. By Pain Type 18.6.2.2.3. By End User 18.6.3. New Mexico Demand Analysis 18.6.3.1. Introduction 18.6.3.2. Demand Analysis and Forecast by Taxonomy 18.6.3.2.1. By Product Type 18.6.3.2.2. By Pain Type 18.6.3.2.3. By End User 19. Structure Analysis 19.1. Demand Analysis by Tier of Companies 19.2. Share Analysis of Top Players 20. Competition Analysis 20.1. Competition Benchmarking 20.2. Branding & Promotional Strategies by Key Players 20.3. Key Development Analysis 20.4. Competition Dashboard 20.5. Competition Deep Dive 20.5.1. ZimVie Inc. 20.5.1.1. Company Overview 20.5.1.2. Product Portfolio 20.5.1.3. Sales Footprint 20.5.1.4. Key Financials 20.5.1.5. SWOT Analysis 20.5.1.6. Key Developments 20.5.1.7. Strategy Overview 20.5.1.7.1. Channel Strategy 20.5.1.7.2. Business Strategy 20.5.1.7.3. Product Strategy 20.5.2. Medtronic 20.5.2.1. Company Overview 20.5.2.2. Product Portfolio 20.5.2.3. Sales Footprint 20.5.2.4. Key Financials 20.5.2.5. SWOT Analysis 20.5.2.6. Key Developments 20.5.2.7. Strategy Overview 20.5.3. Johnson & Johnson 20.5.3.1. Company Overview 20.5.3.2. Product Portfolio 20.5.3.3. Sales Footprint 20.5.3.4. Key Financials 20.5.3.5. SWOT Analysis 20.5.3.6. Key Developments 20.5.3.7. Strategy Overview 20.5.4. Stryker Corporation 20.5.4.1. Company Overview 20.5.4.2. Product Portfolio 20.5.4.3. Sales Footprint 20.5.4.4. Key Financials 20.5.4.5. SWOT Analysis 20.5.4.6. Key Developments 20.5.4.7. Strategy Overview 20.5.5. Abbott Laboratories 20.5.5.1. Company Overview 20.5.5.2. Product Portfolio 20.5.5.3. Sales Footprint 20.5.5.4. Key Financials 20.5.5.5. SWOT Analysis 20.5.5.6. Key Developments 20.5.5.7. Strategy Overview 20.5.6. Boston Scientific Corporation 20.5.6.1. Company Overview 20.5.6.2. Product Portfolio 20.5.6.3. Sales Footprint 20.5.6.4. Key Financials 20.5.6.5. SWOT Analysis 20.5.6.6. Key Developments 20.5.6.7. Strategy Overview 20.5.7. B Braun (Aesculap, Inc) 20.5.7.1. Company Overview 20.5.7.2. Product Portfolio 20.5.7.3. Sales Footprint 20.5.7.4. Key Financials 20.5.7.5. SWOT Analysis 20.5.7.6. Key Developments 20.5.7.7. Strategy Overview 20.5.8. Becton, Dickinson and Company 20.5.8.1. Company Overview 20.5.8.2. Product Portfolio 20.5.8.3. Sales Footprint 20.5.8.4. Key Financials 20.5.8.5. SWOT Analysis 20.5.8.6. Key Developments 20.5.8.7. Strategy Overview 20.5.9. Globus Medical 20.5.9.1. Company Overview 20.5.9.2. Product Portfolio 20.5.9.3. Sales Footprint 20.5.9.4. Key Financials 20.5.9.5. SWOT Analysis 20.5.9.6. Key Developments 20.5.9.7. Strategy Overview 20.5.10. Alphatec Spine, Inc. 20.5.10.1. Company Overview 20.5.10.2. Product Portfolio 20.5.10.3. Sales Footprint 20.5.10.4. Key Financials 20.5.10.5. SWOT Analysis 20.5.10.6. Key Developments 20.5.10.7. Strategy Overview 20.5.11. Nevro Corp 20.5.11.1. Company Overview 20.5.11.2. Product Portfolio 20.5.11.3. Sales Footprint 20.5.11.4. Key Financials 20.5.11.5. SWOT Analysis 20.5.11.6. Key Developments 20.5.11.7. Strategy Overview 20.5.12. NuVasive, Inc. 20.5.12.1. Company Overview 20.5.12.2. Product Portfolio 20.5.12.3. Sales Footprint 20.5.12.4. Key Financials 20.5.12.5. SWOT Analysis 20.5.12.6. Key Developments 20.5.12.7. Strategy Overview 20.5.13. Orthofix US LLC. 20.5.13.1. Company Overview 20.5.13.2. Product Portfolio 20.5.13.3. Sales Footprint 20.5.13.4. Key Financials 20.5.13.5. SWOT Analysis 20.5.13.6. Key Developments 20.5.13.7. Strategy Overview 20.5.14. Surgalign Spine Technologies, Inc. 20.5.14.1. Company Overview 20.5.14.2. Product Portfolio 20.5.14.3. Sales Footprint 20.5.14.4. Key Financials 20.5.14.5. SWOT Analysis 20.5.14.6. Key Developments 20.5.14.7. Strategy Overview 20.5.15. Precision Spine, Inc. 20.5.15.1. Company Overview 20.5.15.2. Product Portfolio 20.5.15.3. Sales Footprint 20.5.15.4. Key Financials 20.5.15.5. SWOT Analysis 20.5.15.6. Key Developments 20.5.15.7. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Spine Pain Industry Analysis in United States
